Valneva IPO Presentation Deck

Key Upcoming Catalysts and Potential Inflection Points Lyme disease vaccine candidate VLA15 ■ Further Phase 2 milestones and read-outs during 2021; Phase 2 study VLA15-221, including pediatric development, initiated March 2021; Chikungunya vaccine candidate VLA1553 ■ Initial Phase 3 data expected mid-2021; Phase 3 now fully recruited COVID vaccine candidate VLA2001 ■ Phase 1/2 initial data reported, Phase 3 data expected in Q3 2021 ■ Regulatory submission planned autumn 2021 assuming clinical data positive Further supply deals subject to negotiations and capacity V Valneva - Roadshow Presentation April 2021 39

View entire presentation